Cannabinergic ligands

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 3-19

  Palmer, Sonya L ^a   Thakur, Ganesh A ^a   Makriyannis, Alexandros ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Anandamide; Anandamide transporter; Cannabimimetics; Cannabinergics; Cannabinoid receptor agonists; Cannabinoid receptor antagonists; Cannabinoid receptors; Fatty acid amide hydrolase

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ADAMANTANE DERIVATIVE; ANANDAMIDE; CANNABINOID; DEXANABINOL; DRONABINOL; LIGAND; METHANANDAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; PROTEIN; RIMONABANT;

ANOREXIA; BINDING SITE; CELL MEMBRANE; CONFERENCE PAPER; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; PAIN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SYNTHESIS;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BIOLOGICAL TRANSPORT; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; LIGANDS; MONOACYLGLYCEROL LIPASES; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

MAMMALIA;

EID: 0037207081     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00143-3     Document Type: Conference Paper

References (87)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. J. Med. Chem. 37:1994;1889.
2. Al-Hayani A., Davies S.N. Cannabinoid receptor mediated inhibition of excitatory synaptic transmission in the rat hippocampal slice is developmentally regulated. Br. J. Pharmacol. 131:2000;663-665.
3. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:2000;84-87.
4. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 375:1995;143-147.
5. Bell M.R., D'Ambra T.E., Kumar V., Eissenstat M.A., Herrmann J.L. Jr, Wetzel J.R., Rosi D., Philion R.E., Daum S.J., Halsta D.J. Antinociceptive (aminoalkyl)indoles. J. Med. Chem. 34:1991;1099-1110.
6. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
7. Beltramo M., de Fonseca F.R., Navarro M., Calignano A., Gorriti M.A., Grammatikopoulos G., Sadile A.G., Giuffrida A., Piomelli D. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J. Neurosci. 20:2000;3401-3407.
8. Boger D.L., Sato H., Lerner A.E., Hedrick M.P., Fecik R.A., Miyauchi H., Wilkie G.D., Austin B.J., Patricelli M.P., Cravatt B.F. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. USA. 97:2000;5044-5049.
9. Breivogel C.S., Childers S.R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. 5:1998;417-431.
10. 8-THC: a novel photoaffinity label of the cannabinoid receptor. J. Med. Chem. 35:1992;3076-3079.
11. Compton D.R., Martin B.R. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J. Pharmacol. Exp. Ther. 283:1997;1138-1143.
12. Cosenza M., Gifford A.N., Gatley S.J., Pyatt B., Liu Q., Makriyannis A., Volkow N.D. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse. 38:2000;477-482.
13. De Lago E., Fernandez-Ruiz J., Ortega-Gutierrez S., Viso A., Lopez-Rodriguez M., Ramos J.A. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur. J. Pharmacol. 449:2002;99-103.
14. Deutsch D.G., Lin S., Hill W.A., Morse K.L., Salehani D., Arreaza G., Omeir R.L., Makriyannis A. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Commun. 231:1997;217-221.
15. Deutsch D.G., Lin S., Hill W.A.G., Morse K.L., Salehani D., Arreaza G., Omeir R.L., Makriyannis A. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Commun. 231:1997;217-221.
16. Deutsch D.G., Omeir R., Arreaza G., Salehani D., Prestwich G.D., Huang Z., Howlett A. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. 53:1997;255-260.
17. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
18. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
19. Di Marzo V., Melck D., Bisogno T., De-Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21:1998;521-528.
20. Drake D.J., Jensen R.S., Busch-Petersen J., Kawakami J.K., Concepcion Fernandez-Garcia M., Fan P., Makriyannis A., Tius M.A. Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized c-6beta methyl, ethyl, and propyl analogues. J. Med. Chem. 41:1998;3596-3608.
21. Edgemond W.S., Greenberg M.J., McGinley P.J., Muthian S., Campbell W.B., Hillard C.J. Synthesis and characterization of diazomethylarachidonyl ketone: an irreversible inhibitor of n-arachidonylethanolamine amidohydrolase. J. Pharmacol. Exp. Ther. 286:1998;184-190.
22. Felder C.C., Joyce K.E., Briley E.M., Glass M., Mackie K.P., Fahey K.J., Cullinan G.J., Hunden D.C., Johnson D.W., Chaney M.O., Koppel G.A., Brownstein M. Ly320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of camp accumulation. J. Pharmacol. Exp. Ther. 284:1998;291-297.
23. Gaoni Y., Mechoulam R. Hashish. III: Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
24. Gareau Y., Dufresne C., Gallant M., Rochette C., Sawyer N., Slipetz D.M., Tremblay N., Weech P.K., Metters K.M., Labelle M. Structure activity relationships of tetrahydrocanabinol analogs on human cannabinoid receptors. Bioorg. Med. Chem. Lett. 6:1996;189-194.
25. Gatley S.J., Lan R., Pyatt B., Gifford A.N., Volkow N.D., Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole am251 to rodent brain cannabinoid receptors. Life Sci. 61:1997;191-197.
26. Gatley S.J., Lan R., Volkow N.D., Pappas N., King P., Wong C.T., Gifford A.N., Pyatt B., Dewey S.L., Makriyannis A. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J. Neurochem. 70:1998;417-423.
27. Gerard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. J. Biochem. 279:1991;129-134.
28. Gifford A.N., Tang Y., Gatley S.J., Volkow N.D., Lan R., Makriyannis A. Effect of the cannabinoid receptor spect agent, am 281, on hippocampal acetylcholine release from rat brain slices. Neurosci. Lett. 238:1997;84-86.
29. Gifford A.N., Bruneus M., Lin S., Goutopoulos A., Makriyannis A., Volkow N.D., Gatley S.J. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (am 374). Eur. J. Pharmacol. 383:1999;9-14.
30. Giuffrida A., Rodriguez de Fonseca F., Nava F., Loubet-Lescoulie P., Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur. J. Pharmacol. 408:2000;161-168.
31. Gonzalez S., Romero J., de Miguel R., Lastres-Becker I., Villanua M.A., Makriyannis A., Ramos J.A., Fernandez-Ruiz J.J. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci. 65:1999;327-336.
32. Goutopoulos A., Makriyannis A. From cannabis to cannabinergics new therapeutic opportunities. Pharmacol. Ther. 95:2002;103-117.
33. Goutopoulos A., Fan P., Khanolkar A.D., Xie X.Q., Lin S., Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg. Med. Chem. 9:2001;1673-1684.
34. Guo Y., Abadji V., Morse K.L., Fournier D.J., Li X., Makriyannis A. (-)-11-hydroxy-7′-isothiocyanato-1′,1′-dimethylheptyl-delta 8-thc: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain. J. Med. Chem. 37:1994;3867-3870.
35. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
36. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R.G., Ross R.A., Mechoulam R., Fride E. Hu-308: a specific agonist for CB (2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA. 96:1999;14228-14233.
37. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;3662-3665.
38. Harrington P.E., Stergiades I.A., Erickson J., Makriyannis A., Tius M.A. Synthesis of functionalized cannabinoids. J. Org. Chem. 65:2000;6576-6582.
39. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
40. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54:2002;161-202.
41. Huffman J.W., Yu S., Showalter V., Abood M.E., Wiley J.L., Compton D.R., Martin B.R., Bramblett R.D., Reggio P.H. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem. 39:1996;3875-3877.
42. Izzo A.A., Mascolo N., Tonini M., Capasso F. Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum. Br. J. Pharmacol. 129:2000;984-990.
43. Johnson M.R., Melvin L.S. The Discovery of Nonclassical Cannabinoid Analgesics. 1986;CRC Press, Boca Raton.
44. Kendall D. Sr-141716a sanofi-synthelabo. Curr. Opin. Centr. Periph. Nervous Sys. Investigat. Drugs. 2:2000;112-122.
45. Khanolkar A.D., Makriyannis A. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Life Sci. 65:1999;607-616.
46. Khanolkar A.D., Abadji V., Lin S., Hill W.A., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39:1996;4515-4519.
47. Khanolkar A.D., Palmer S.L., Makriyannis A. Molecular probes for the cannabinoid receptors. Chem. Phys. Lipids. 108:2000;37-52.
48. Koutek B., Prestwich G.D., Howlett A.C., Chin S.A., Salehani D., Akhavan N., Deutsch D.G. Inhibitors of arachidonoyl ethanolamide hydrolysis. J. Biol. Chem. 269:1994;22937-22940.
49. Lan R., Liu Q., Fan P., Lin S., Fernando S.R., McCallion D., Pertwee R., Makriyannis A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 42:1999;769-776.
50. Lang W., Qin C., Lin S., Khanolkar A.D., Goutopoulos A., Fan P., Abouzid K., Meng Z., Biegel D., Makriyannis A. Substrate specificity and stereoselectiviy of rat brain microsomal anandamide amidohydrolase. J. Med. Chem. 42:1999;896-902.
51. Lin S., Khanolkar A.D., Pusheng F., Goutopoulos A., Qin C., Papahadjis D., Makriyannis A. Novel analogues of arachidonylethanolamide (anandamide) affinities for CB1 and CB2 cannabinoid receptors and metabolic stability. J. Med. Chem. 41:1998;5353-5361.
52. Little P.J., Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247:1988;1046-1051.
53. Lu, D., Khanolkar, A., Meng, Z., Fan, P., Reggio, P.H., Makriyannis, A., 1997. CB1/CB2 Selective Cannabinoids by Conformational Constraint of the Side Chain. Book of Abstracts, International Cannabinoid Research Society, Stone Mountain, held in Atlanta, GA, June 20-22.
54. Maccarrone M., van der Stelt M., Rossi A., Veldink G.A., Vliegenthart J.F., Agro A.F. Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273:1998;32332-32339.
55. Makriyannis A., Rapaka R.S. The molecular basis of cannabinoid activity. Life Sci. 47:1990;2173-2184.
56. Makriyannis, A., Khanolkar, A., 2001. Dibenzopyranone derivative peripheral cannabinoid receptor (CB2) selective ligands, their preparation, and their therapeutic use. PCT Int. Appl., 33 pp.
57. Malan T.P. Jr, Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
58. Martin B.R., Beletskaya I., Patrick G., Jefferson R., Winckler R., Deutsch D.G., Di Marzo V., Dasse O., Mahadevan A., Razdan R.K. Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 294:2000;1209-1218.
59. Matsuda L.A., Lolait S.J., Brownstein M.J., Bonner T.I. Stucture of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;61-564.
60. Maurelli S., Bisogno T., De Petrocellis L., Di Luccia A., Marino G., Di Marzo V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett. 377:1995;82-86.
61. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
62. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359:1998;1-18.
63. Mechoulam, R., Devane, W.A., Glaser, R., Cannabinoid geometry and biological activity. Marihuana and Medicine. Conference on Marihuana and Medicine, New York, March 20-21 (1998), 1999, pp. 65-90.
64. Mignani, S., Hittinger, A., Achard, D., Bouchard, H., Bouquerel, J., Capet, M., Grisoni, S., Malleron, J.-L., 2000. Preparation of 1-bis(aryl)methyl-3-(alkylsulfonyl)arylmethyleneazetidines as cannabinoid CB1 receptor antagonists. PCT Int. Appl., 239 pp.
65. Morse K.L., Fournier D.J., Li X., Grzybowska J., Makriyannis A. A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci. 56:1995;1957-1962.
66. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
67. Musty R.E. Cannabinoid therapeutic potential in motivational processes, psychological disorders and central nervous system disorders. Onaivi E.S. Biology of Marijuana. 2002;45-74 Taylor & Francis, London, UK.
68. Muthian S., Nithipatikom K., Campbell W.B., Hillard C.J. Synthesis and characterization of a fluorescent substrate for the n-arachidonoylethanolamine (anandamide) transmembrane carrier. J. Pharmacol. Exp. Ther. 293:2000;289-295.
69. Nakamura-Palacios E.M., Moerschbaecher J.M., Barker L.A. The pharmacology of SR 141716a: a review. CNS Drug Rev. 5:1999;43-58.
70. Papahatjis D.P., Kourouli T., Abadji V., Goutopoulos A., Makriyannis A. Pharmacophoric requirements for cannabinoid side chains: multiple bond and c1′-substituted delta 8-tetrahydrocannabinols. J. Med. Chem. 41:1998;1195-1200.
71. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
72. Pertwee R.G. Advances in cannabinoid receptor pharmacology. Med. Aromat. Plants - Ind. Prof. 4:1998;125-174.
73. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp. Opin. Investig. Drugs. 9:2000;1553-1571.
74. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63:2001;569-611.
75. Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacol. Ther. 95:2002;165-174.
76. Pertwee R., Griffin G., Fernando S., Li X., Hill A., Makriyannis A. Am630, a competitive cannabinoid receptor antagonist. Life Sci. 56:1995;1949-1955.
77. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA. 96:1999;5802-5807.
78. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38:1986;75-149.
79. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., Le Fur G.L. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
80. Ross R.A., Brockie H.C., Fernando S.R., Saha B., Razdan R.K., Pertwee R.G. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br. J. Pharmacol. 125:1998;1345-1351.
81. Ross R.A., Brockie H.C., Stevenson L.A., Murphy V.L., Templeton F., Makriyannis A., Pertwee R.G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of l759633, l759656 and AM630. Br. J. Pharmacol. 126:1999;665-672.
82. Ross R.A., Gibson T.M., Stevenson L.A., Saha B., Crocker P., Razdan R.K., Pertwee R.G. Structural determinants of the partial agonist-inverse agonist properties of 6′-azidohex-2′-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Br. J. Pharmacol. 128:1999;735-743.
83. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
84. Schuel H., Chang M.C., Burkman L.J., Picone R.P., Makriyannis A., Zimmerman A.M., Zimmerman S. Cannabinoid receptors in sperm. Nahas G.G., Sutim K.M., Augerell S. Marijuana and Medicine. 1999;335-345 Humana Press, Totowa.
85. Thakur, G.A., Palmer, S.L., Harrington, P.E., Stergiades, I.A., Tius, M.A., Makriyannis, A., 2002. J. Biochem. Biophys. Meth. (in press).
86. Tius M.A., Makriyannis A., Zou X.L., Abadji V. Conformationally restricted hybrids of CP-55,940 and HHC: stereoselective synthesis and activity. Tetrahedron. 50:1994;2671-2680.
87. Tius M.A., Hill W.A.G., Zou X.L., Busch-Petersen J., Kawakami J.K., Fernandez-Garcia M.C., Drake D.J., Abadji V., Makriyannis A. Classical/non-classical cannabinoid hybrids; stereochemical requirements for the southern hydroxyalkyl chain. Life Sci. 56:1995;2007-2012.